William Blair Investment Management LLC Purchases Shares of 570,153 Krystal Biotech, Inc. $KRYS

William Blair Investment Management LLC purchased a new stake in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 570,153 shares of the company’s stock, valued at approximately $211,909,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in KRYS. BlackRock Inc. purchased a new position in shares of Krystal Biotech in the second quarter worth approximately $1,554,113,000. Avoro Capital Advisors LLC increased its holdings in Krystal Biotech by 4.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock valued at $712,226,000 after buying an additional 111,111 shares during the last quarter. State Street Corp raised its position in Krystal Biotech by 10.5% in the second quarter. State Street Corp now owns 1,355,346 shares of the company’s stock worth $186,306,000 after acquiring an additional 128,639 shares during the period. Soleus Capital Management L.P. raised its position in Krystal Biotech by 108.9% in the second quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Krystal Biotech by 5.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock worth $94,261,000 after acquiring an additional 28,075 shares during the last quarter. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on KRYS shares. TD Cowen boosted their price objective on shares of Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Royal Bank Of Canada started coverage on Krystal Biotech in a report on Friday, August 14th. They issued an “outperform” rating and a $400.00 target price on the stock. Bank of America lifted their target price on Krystal Biotech from $364.00 to $396.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th. Evercore reissued an “outperform” rating and set a $300.00 price target on shares of Krystal Biotech in a report on Tuesday, May 5th. Finally, Wall Street Zen lowered Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $365.40.

Insider Buying and Selling

In other Krystal Biotech news, Director Dino A. Rossi sold 25,000 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $329.12, for a total value of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at approximately $16,456,000. This represents a 33.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP John Charles Thomas sold 1,000 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares in the company, valued at approximately $347,270. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 51,642 shares of company stock valued at $16,471,923. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Price Performance

KRYS opened at $346.58 on Friday. The firm has a market cap of $10.26 billion, a P/E ratio of 43.43 and a beta of 0.53. Krystal Biotech, Inc. has a 1-year low of $136.73 and a 1-year high of $382.54. The company has a 50 day simple moving average of $347.03 and a two-hundred day simple moving average of $301.40.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings data on Monday, August 3rd. The company reported $1.79 EPS for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million for the quarter, compared to the consensus estimate of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. Equities analysts anticipate that Krystal Biotech, Inc. will post 7.68 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.